
May 27 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O:
ROCKET PHARMACEUTICALS PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF RP-A501 FOR DANON DISEASE
ROCKET PHARMACEUTICALS INC - IN ACTIVE DIALOGUE WITH FDA AFTER SAE IN RP-A501 TRIAL
ROCKET PHARMACEUTICALS INC - FDA PLACES CLINICAL HOLD ON RP-A501 TRIAL AFTER SAE
ROCKET PHARMACEUTICALS INC - PATIENT IN RP-A501 PHASE 2 TRIAL EXPERIENCES SERIOUS ADVERSE EVENT
ROCKET PHARMACEUTICALS INC - EXPECTS RESOURCES TO FUND OPERATIONS INTO 2027
ROCKET PHARMACEUTICALS INC - UNABLE TO PROVIDE GUIDANCE ON ANTICIPATED TIMING FOR COMPLETION OF PHASE 2 TRIAL